Discover how a recent case links COVID-19 and corticosteroid treatment to the unusual onset of bilateral central serous chorioretinopathy, shedding light on the long-term ocular impacts of the pandemic.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
A 30-Year-Old Man with a Recent History of COVID-19 Requiring Treatment with Corticosteroids Who Developed Bilateral Central Serous Chorioretinopathy During 7-Month Follow-Up.
Angelidis et al., Am J Case Rep 2023
DOI: 10.12659/AJCR.940241
Summary of Case Report on Corticosteroid-Induced Central Serous Chorioretinopathy
What’s New: This case report details a rare instance of bilateral central serous chorioretinopathy (CSCR) with unilateral fibrin development in a 30-year-old man following corticosteroid treatment for COVID-19.
Importance: It underscores the potential ocular side effects of corticosteroids, emphasizing the need for ophthalmological monitoring in patients with sudden vision loss after corticosteroid use.
Contribution to Literature: The report contributes to the understanding of CSCR as a possible complication of corticosteroid therapy, particularly in the context of COVID-19 treatment, and suggests the necessity for extended follow-up due to the dynamic nature of the condition.
The patient, after receiving a week of intravenous dexamethasone and a tapering course of oral methylprednisolone, experienced bilateral visual acuity deterioration and was diagnosed with acute CSCR. Over a 7-month follow-up, his visual acuity improved and stabilized, but optical coherence tomography (OCT) findings continued to evolve.
Conclusions: The case highlights the link between corticosteroid use and CSCR, advocating for careful ophthalmological evaluation and follow-up in similar clinical scenarios.